

MAR-05-2002 TUE 03:07 PM SALIWANCHIK, LLOYD & SALIWA

FAX NO: 352 372 5800

P. 01

Rec'd PCT/PTC 05 MAR 2002

FACSIMILE COVER SHEET

1600
SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association
2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

Telephone (352) 375-8100
Facsimile (352) 372-5800

RECEIVED

APR 01 2002

TECH CENTER 1600/2900

TO: OIPE

FROM: Frank C. Eisenschenk, Ph.D.
(Reg. No. 45,332)

COMPANY: U.S. Patent & Trademark Office

DATE: March 5, 2002

FAX NO.: (703) 308-7751

NO. OF PAGES:
(INCLUDING COVER SHEET) 5

SUBJECT/MESSAGE:

U.S. Patent Application Docket No. SPO-103
Peptide-based Immunotherapeutic Agent for Treating Allergic Diseases
(Sone, *et al.*)
Serial No. 09/142,524; filed September 9, 1998

**THIS IS AN OFFICIAL DOCUMENT.
PLEASE DELIVER IMMEDIATELY. Thank you.**


Attachments: Request for Corrected Filing Receipt
Redlined Copy of February 7, 2002 Filing Receipt

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on March 5, 2002.

BOX OIPE
Patent Application
Docket No. SPO-103
Serial No. 09/142,524


Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : M. DiBrino, Ph.D.
Art Unit : 1644
Applicant(s) : Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama, Kohsuke Kino
Serial No. : 09/142,524
Filed : September 9, 1998
Confirm No. : 2300
For : Peptide-Based Immunotherapeutic Agent for Treating Allergic Diseases

BOX OIPE
Commissioner for Patents
Washington, D.C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Applicants respectfully request a corrected Filing Receipt wherein the filing date be corrected to the actual filing date of September 9, 1998, instead of the 102(e) date of January 4, 1999.

Also, based on the July 12, 2001 CPA submission, the total claims are 24 (not 9), and the number of independent claims are 2 (not 1).


A redlined copy of the February 7, 2002 Filing Receipt, as received from the U.S. Patent and Trademark Office, is enclosed.

2

Docket No. SPO-103
Serial No. 09/142,524

If any further information or documentation is required in order to accede to this request for a corrected Filing Receipt, the Office is respectfully requested to contact the undersigned by telephone at (352)375-8100.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/jaj

Attachment: Redlined copy of February 7, 2002 Filing Receipt




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FILE FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/142,524	01/04/1999 9/9/1998	1644	1384	SPO-103	18	24	12

CONFIRMATION NO. 2300

DAVID R SALIWANCHIK
2421 N W 41ST STREET
SUITE A 1
GAINESVILLE, FL 326066669

CORRECTED FILING RECEIPT

0C00000007435830

Date Mailed: 02/07/2002

Receipt is acknowledged of a CPA in this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

TOSHIO SONE, KANAGAWA, JAPAN;
AKINORI KIUME, KANAGAWA, JAPAN;
KAZUO DAIRIKI, KANAGAWA, JAPAN;
AKIKO IWAMA, KANAGAWA, JAPAN;
KOHISUKE KINO, KANAGAWA, JAPAN;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/JP97/00740 03/10/1997

Foreign Applications

If Required, Foreign Filing License Granted 02/06/2002

CPA filed on: 07/12/2001

Projected Publication Date: 05/16/2002

Non-Publication Request: No

Early Publication Request: No

Title

PEPTIDE-BASED IMMUNOTHERAPEUTIC AGENT FOR TREATING ALLERGIC DISEASES

Preliminary Class

435

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).